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Abstract
Background.—Point-of-care testing (POCT) assays for chlamydia are being developed. Their 
potential impact on the burden of chlamydial infection in the United States, in light of suboptimal 
screening coverage, remains unclear.
Methods.—Using a transmission model calibrated to data in the United States, we estimated the 
impact of POCT on chlamydia prevalence, incidence, and chlamydia-attributable pelvic 
inflammatory disease (PID) incidence, assuming status quo (Analysis 1) and improved (Analysis 
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2) screening frequencies. We tested the robustness of results to changes in POCT sensitivity, the 
proportion of patients getting treated immediately, the baseline proportion lost to follow-up 
(LTFU), and the average treatment delay.
Results.—In Analysis 1, high POCT sensitivity was needed to reduce the chlamydia-associated 
burden. With a POCT sensitivity of 90%, reductions from the baseline burden only occurred in 
scenarios in which over 60% of the screened individuals would get immediate treatment and the 
baseline LTFU proportion was 20%. With a POCT sensitivity of 99% (baseline LTFU 10%, 2-
week treatment delay), if everyone were treated immediately, the prevalence reduction was 
estimated at 5.7% (95% credible interval [CrI] 3.9–8.2%). If only 30% of tested persons would 
wait for results, the prevalence reduction was only 1.6% (95% CrI 1.1–2.3). POCT with 99% 
sensitivity could avert up to 12 700 (95% CrI 5000–22 200) PID cases per year, if 100% were 
treated immediately (baseline LTFU 20% and 3-week treatment delay). In Analysis 2, when POCT 
was coupled with increasing screening coverage, reductions in the chlamydia burden could be 
realized with a POCT sensitivity of 90%.
Conclusions.—POCT could improve chlamydia prevention efforts if test performance 
characteristics are significantly improved over currently available options.
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Point-of-care testing (POCT) refers to testing done at or near the site of the patient’s care, 
where the result leads to immediate diagnosis and treatment and, consequently, 
improvements in the patient’s care. The World Health Organization (WHO) considers the 
lack of POCT for sexually transmitted infections (STI) to be an obstacle for global STI 
prevention [1]. Previous analyses, using static models, indicated that POCT for chlamydia 
infections could reduce the costs and incidence of pelvic inflammatory disease (PID), 
compared to standard testing, in the United States [2] and in the United Kingdom [3]. The 
lifetime risk of chlamydia and associated reproductive health outcomes remain at high levels 
in the United States [4], yet the population-level impact of POCT, accounting for 
transmission dynamics of chlamydia and current levels of chlamydia prevention, has not 
been evaluated.
A common feature in candidate POCT assays has been lower sensitivity, compared to 
nucleic acid amplification tests (NAATs) [5]. In high-burden settings with limited access to 
screening, POCT with moderate sensitivity may yield significant benefits [6, 7]. In the 
United States, NAATs with high sensitivity is the standard in diagnosing chlamydial 
infection [8], and chlamydia screening has been widely implemented [9]. Reduced test 
sensitivity may increase the risk of PID, as suggested in a retrospective cohort study in 
which women with negative antigen-based results had 17% higher odds of being diagnosed 
with PID over the next year, compared to women with negative NAAT results [10]. 
However, POCT could bring additional benefits in settings where delays between diagnosis 
and treatment, as well as the loss to follow-up (LTFU) of diagnosed individuals prior to 
treatment, are common [11–15]. Despite national guidelines recommending annual 
chlamydia screening in sexually active women <25 years old, annual chlamydia screening 
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was estimated as 47–58% among sexually active women enrolled in different healthcare 
plans in the United States in 2017 [16]. POCT, coupled with other interventions, could 
facilitate wider access to chlamydia testing.
Several candidate POCT assays are in development; as they are introduced to the market, 
their potential impacts need to be evaluated in order to guide POCT adoption and to verify 
that they are able to improve chlamydia prevention. Implementing novel technologies 
requires forecasting factors that create uncertainty in their potential benefits, such as the 
willingness of patients to wait for their results. The aim of this study was to estimate the 
population-level health benefits that may be attained through the use of a future point-of-
care test. We accounted for 2 possible avenues of improvement, and potential uncertainties 
in these: (1) reduced LTFUs and treatment delays; and (2) expanded screening coverage, 
facilitated by POCT together with other novel interventions. Using a mathematical 
transmission model calibrated to data in the United States, we evaluated the impact of a 
point-of-care test on the chlamydia prevalence and incidence, and chlamydia-attributable 
PID cases, under a range of different scenarios, reflecting uncertainty in the POCT 
characteristics and the status quo care conditions.
METHODS
Factors we considered to influence POCT are presented in Table 1. The potential effects of 
POCT were quantified by comparing scenarios in which POCT would be adopted to the 
status quo, using estimates of current prevention efforts that were generated by the calibrated 
chlamydia transmission model.
Chlamydia Transmission Model
We used a deterministic pair formation model capturing chlamydia transmission in a 
heterosexual population [17]. The model stratified the population by age, sex, partnership 
status, sexually risky behavior, and chlamydia infection status. Age was divided into 4 
categories: 15–18, 19–24, 25–39, and 40–54 years old. Natural history was represented 
using a susceptible-infected-susceptible structure, differentiating asymptomatic and 
symptomatic infections and the first infection from subsequent infections. Testing 
symptomatic people was varied by sex, screening asymptomatic people was varied by sex 
and age, and natural recovery was varied by sex. Partner notification was modeled explicitly 
in long-term partnerships. The model was calibrated to United States age- and sex-specific 
estimates of chlamydia prevalences and case reports in a Bayesian framework. Prevalence 
estimates for ages 15–39 were obtained from the National Health and Nutrition and 
Examination Survey for the years 1999–2014 for each age group in the model, up to age 39 
[18]. National case reports for the years 2000–2015 were obtained by sex and age groups 
[19]. We also calibrated the model to the proportion of 15- to 18-year-old individuals who 
reported ever having had sex, using data from the Youth Risk Behavioral Survey for 1999–
2015 [20].
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Development of Pelvic Inflammatory Disease due to Chlamydial Infection
The development of PID was included as a rate from the chlamydia-infected health states, 
assuming the risk of PID as constant over the course of the infection. The annual rate of PID 
due to chlamydia was estimated through evidence synthesis [21], and it is approximated well 
by a normally distributed variable with a mean of 0.154 and standard deviation of 0.049. We 
assumed the rate pertains to first-time infections, with a higher risk among those with repeat 
infections, at a fixed relative rate of 1.15, based on evidence from longitudinal studies [22, 
23].
Outcomes and Analyses
We sampled 200 model simulations from the posterior distribution of the calibrated model 
and 40 values from the distribution of PID risk, resulting in 8000 parameter combinations 
used in this analysis. We assumed POCT would replace all chlamydia testing after the last 
year of model calibration, and the outcomes were estimated at equilibrium (40 years after 
POCT implementation) to quantify the intervention’s maximum impact. We compared each 
POCT scenario against the model-estimated status quo, estimating the existing chlamydia 
prevention efforts. In the status quo, we maintained screening at 2015 levels, as estimated in 
the calibrated model, and used a constant population size. We report the relative prevalence 
reduction, yearly infections averted, and yearly incident PID averted for women using means 
and 95% credible intervals [CrIs]. Women aged 15–24 years are most affected by chlamydia 
and were the focus of the analysis.
We completed 2 analyses: in Analysis 1, we implemented POCT without changing the 
screening rate; and in Analysis 2, we assumed that POCT was implemented with a modest 
increase in the screening rate, facilitated by other interventions (eg, testing outside the clinic 
setting). We varied some of the uncertainties that can influence the impact of POCT, the first 
2 of which pertain to the point-of-care test characteristics and the last 2 of which pertain to 
population characteristics:
1. The sensitivity of the point-of-care test was varied between 90–99%.
2. The POCT turnaround time, and how it impacts patients’ willingness to wait for 
test results, was examined. In its most idealized form, POCT could remove 100% 
of LTFUs and treatment delays. This assumes the POCT results are generated 
quickly enough for everyone to receive their results and treatment during the 
same patient visit. A 20-minute wait time for POCT is the WHO goal [1], but 
only 60% of women screened for chlamydia indicated that they would be willing 
to wait for that amount of time, and 30% responded that they would be willing to 
wait 40 minutes [24]. In Analysis 1, we varied the proportion receiving 
immediate treatment between 30–100%. In Analysis 2, where increased 
screening was implemented, 30–60% received immediate treatment.
3. The baseline levels of LTFU in the population in the absence of POCT were 
varied between 5–20% (Table 1).
4. The baseline level of an average treatment delay in the absence of POCT was 
varied between 1–3 weeks (Table 1).
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We assumed LTFUs and treatment delays pertained only to asymptomatic infections.
Accounting for Delayed Treatment and Loss to Follow-up
In the model, screening and treatment were operationalized simultaneously. The model-
estimated rate of transition from infected to susceptible represents the effective treatment 
rate given a person was tested, retained in follow-up, and received treatment, and is equal to 
the inverse of the average duration from infection to treatment initiation (Obase) for 
asymptomatic women. For sexually active women 15–18 years old in 2015, the effective 
treatment rate was estimated as 0.69 per year (median, with interquartile range [IQR] 0.66–
0.72). For women 19–24 years old, it was 0.52 (IQR 0.34–0.70), and for women 25–39 years 
old, it was 0.12 (IQR 0.10–0.15). A relative frequency was estimated for the same age 
groups of men and applied as a multiplier to the correspondent effective treatment rate for 
women in the same age group. For men 15–24 years old, the relative frequency was 0.14 
(IQR 0.11–0.17) of the women’s rate, and for men 25–39 years old, the frequency was 0.02 
(IQR 0.02–0.02) of the women’s rate. In the United States, no recommendations exist for 
screening heterosexual men, but men in high-burden areas are encouraged to be screened 
when resources allow [25]. Limited screening of men occurs in some institutional settings 
(such as the military [26], schools [27], and the US National Job Training Program [28]). 
For women and men aged 40–54 years, we assumed no routine screening.
Using the duration from infection to treatment initiation (Obase), we could back-calculate the 
duration between screening tests, depending on the assumptions about LTFU and treatment 
delay: in Obase = (T + D)/(1 − f), T is the duration between screening tests, f is the 
proportion LTFU after screening, and D is the average duration between testing and 
treatment initiation among those not LTFU. POCT with a short test turnaround, which would 
remove LTFUs and treatment delays, could reduce the duration of infection by shortening 
time to treatment. Among those receiving testing and treatment on the same visit, the mean 
time to treatment initiation would be OPOCT = T = Obase (1 − f) − D. If treatment were not 
immediate, the average duration to treatment initiation would be Opartial = pOPOCT + (1 − p) 
Obase, where p is the proportion who wait for their test results. To increase the rate of 
screening by 20% from the levels estimated in the calibrated model, we used the duration 
between tests, T, and the assumed levels of LTFU and treatment delays: Tnew = (Obase[1 − f] 
− D)/1.2. This can be used in OPOCT_new = Tnew and Opartial_new = pOPOCT_new + (1 − p) 
Obase_new, where Obase_new =
Tnew + D
1 − f .
RESULTS
In Analysis 1, we considered scenarios in which all current testing would be replaced by 
POCT (Figure 1). POCT’s impact increases with increased test sensitivity, shorter 
turnaround times for POCT, and larger baseline LTFUs and treatment delays, which would 
be removed or reduced in the POCT scenarios. With a POCT sensitivity of 90%, reductions 
from the baseline burden only occurred in scenarios in which over 60% of the screened 
individuals would get immediate treatment and the baseline LTFU was 20%. When POCT 
sensitivity is on par with currently implemented testing (test sensitivity 99%), improvements 
were estimated across the analyzed scenarios.
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In the calibrated model, the mean prevalence in women aged 15–24 years in equilibrium was 
2.9% (95% CrI 2.4–3.4%). Using the scenario where the population baseline LTFU 
probability is 10% with a 2-week treatment delay as an example, implementing POCT with 
a sensitivity of 95% and with 100% of patients receiving immediate treatment was estimated 
to result in a prevalence reduction of 3.5% (95% CrI 2.3–5.1%), which corresponds to a 
chlamydia prevalence of 2.8% (95% CrI 2.3–3.3%). If only 30% waited for results and 
received immediate treatment, POCT would not be beneficial, but rather would result in a 
slight increase in prevalence, of 0.5% (95% CrI increase of 0.4–0.6%). If POCT sensitivity 
is 99%, more substantial benefits are possible; if 100% receives immediate treatment, the 
prevalence reduction was estimated at 5.7% (95% CrI 3.9–8.2%), corresponding to a 
chlamydia prevalence of 2.8% (95% CrI 2.2–3.2%). If only 30% waited for their results, the 
prevalence reduction would be 1.6% (95% CrI 1.1–2.3%).
Similar trends were observed for the other outcomes examined: POCT with 99% sensitivity 
could avert between 800 (95% CrI 300–1500) and 12 700 (95% CrI 5000–22 200) cases of 
PID per year, with the smaller number corresponding to 30% treated immediately, a 5% 
baseline LTFU rate, and a 1-week baseline delay, and the larger number corresponding to 
100% treated immediately, a 20% baseline LTFU rate, and a 3-week baseline delay. The 
respective numbers for average yearly infections averted were estimated at 2100 (95% CrI 
600–4500) and 38 400 (95% CrI 11 300–78 000).
In Analysis 2, we considered additional scenarios in which POCT is accompanied by other 
improvements in chlamydia screening (Figure 2). With a 20% increase in screening 
frequency over baseline, we expect that reductions in the chlamydia burden compared to 
baseline would be seen with lower levels of POCT sensitivity than those required in 
Analysis 1. With sensitivity of 99%, 100% treated immediately, a 20% LTFU rate, and a 3-
week treatment delay at baseline, POCT plus enhanced screening would reduce the 
prevalence by 15.0% (95% CrI 10.6–20.9%), corresponding to a new prevalence level of 
2.5% (95% CrI 1.9–3.0%). The impact of immediate treatment was more pronounced when 
baseline LTFUs and treatment delays were larger.
The findings for Analyses 1 and 2 were similar among women aged 25–39 and 40–54, with 
diminishing impact of POCT for the older age groups (Supplementary Figures 1–4).
DISCUSSION
In this study, we estimated the potential benefits achievable if chlamydia POCT were 
implemented in the United States under varied assumptions about the point-of-care test and 
population characteristics. We employed a transmission model of chlamydia, calibrated to 
national-level data on chlamydia epidemiology in the United States. Current prevention 
efforts for chlamydia are already maintaining a lower burden of infection compared to what 
would occur in the absence of screening [17]. A strength of the study is its ability to 
incorporate estimates of the impact of current prevention strategies, making assessments of 
the incremental benefits of novel strategies more robust. Improving chlamydia prevention 
over the status quo will likely require high standards from POCT. POCT with a sensitivity 
close to currently used NAATs could offer substantial additional benefits for chlamydia 
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prevention. POCT with a lower sensitivity may increase the chlamydia burden, unless there 
are other factors coupled with POCT that can increase the level of screening at the 
population level.
Some of our assumptions may overestimate the impact of POCT, whilst others may 
underestimate its impact. The manner in which baseline LTFUs and treatment delays were 
incorporated may have overestimated the effect of POCT, as we adjusted the overall 
treatment rate instead of accounting for the heterogeneity in the population and improved 
outcomes that would occur for a subset of the population. Furthermore, if people were to 
reduce their risk behavior between receiving a positive diagnosis and being treated, this 
would overestimate the impact of POCT in our model, as we included no behavior changes. 
The estimate of the POCT impact would likely be lower using an individually based model, 
as an individual-based model is able to account for the individual-level variability in 
treatment times and LTFUs in the population. An individual based model would also 
account for the network-level factors whereby the main partners of an infected index case 
are likely to already be infected with chlamydia themselves, which would limit the onward 
transmission potential of the infection during the treatment delay and LTFU. The pair 
formation model framework utilized in this study captures some partnership dynamics, but 
not full network effects. However, the overall conclusion of the study remains robust to the 
underlying assumptions: knowing we are likely overestimating the impact of POCT 
strengthens the finding of needing a high-sensitivity point-of-care test to ensure beneficial 
outcomes at the population level. Our assumption that the impact of prolonged waiting times 
would cause patients who leave to experience the same level of LTFU and delay as in the 
baseline prior to POCT may underestimate the impact of POCT: even if patients leave before 
receiving test results, faster turnaround times for test results could help facilitate faster 
treatment times, as the Dean St. Express clinic has shown [29]. In the Dean St Express 
clinic, patients are contacted on the day of testing to inform them of the results, which has 
shortened treatment initiation times. If POCT were combined with other innovative models 
to expand chlamydia testing and to deliver test results to patients more quickly, this would 
diversify the ways in which POCT may be implemented. The study presents an evaluation of 
hypothetical point-of-care tests not yet available, and the results should be taken as 
exploratory in nature.
There are wider research needs regarding the practical aspects of POCT roll-out and the 
future of STI control in the presence of novel prevention strategies, which were outside the 
scope of this study but warrant future research. The inclusion of economic outcomes and 
cost effectiveness are further avenues for research. In the future, POCT for chlamydia may 
be part of a multiplex assay [30], which will require a more comprehensive analysis of 
benefits and harms. More research is also required if the direction of POCT is towards self-
collection or even self-testing kits. Home testing can achieve a similar level of index case 
management as clinic-based testing, but it is not clear whether more infections are identified 
[31]. Testing outside the clinic setting may result in similar challenges as expedited partner 
therapy, with concerns about the prescription of antibiotics without seeing the patient [32, 
33]. The surveillance of STIs is based on clinic and laboratory notifications of positive 
chlamydia test results, and the ability of surveillance to track changes in the disease burden 
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may need to be realigned with novel testing methods if testing outside clinics became more 
common [34].
CONCLUSIONS
POCT can enhance chlamydia prevention efforts, but the magnitude of benefits depends on 
the state of care, including status quo levels of LTFUs and treatment delays, and the degrees 
to which POCT can improve these. These findings highlight the importance of 
understanding both the test characteristics and patient care–specific characteristics prior to 
the implementation of POCT. The evaluation of the technologies in development and in the 
implementation phase is a vital part of the improvement and planning of STI control. 
Aspects such as which outcomes to measure and what data to collect should be continually 
assessed. Candidate POCT assays for chlamydia are in development, and these have the 
potential to reduce the chlamydia burden if implemented in an effective manner.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments.
The authors thank Christian Testa for his advice on figure formatting.
Financial support. This work was supported by the National Center for Human Immunodeficiency Virus, Viral 
Hepatitis, Sexually Transmitted Disease, and Tuberculosis Prevention Epidemiologic and Economic Modeling 
Agreement (grant number 5NU38PS004644) of the US Centers for Disease Control and Prevention.
References
1. World Health Organization. Point-of-care diagnostic tests (POCTs) for sexually transmitted 
infections (STIs). Geneva, Switzerland: World Health Organization, 2017 Available at: http://
www.who.int/reproductivehealth/topics/rtis/pocts/en/. Accessed 31 March 2018.
2. Gift TL, Pate MS, Hook EW 3rd, Kassler WJ. The rapid test paradox: when fewer cases detected 
lead to more cases treated: a decision analysis of tests for Chlamydia trachomatis. Sex Transm Dis 
1999; 26:232–40. [PubMed: 10225593] 
3. Turner KM, Round J, Horner P, et al. An early evaluation of clinical and economic costs and 
benefits of implementing point of care NAAT tests for Chlamydia trachomatis and Neisseria 
gonorrhoea in genitourinary medicine clinics in England. Sex Transm Infect 2014; 90:104–11. 
[PubMed: 24273127] 
4. Chambers LC, Khosropour CM, Katz DA, Dombrowski JC, Manhart LE, Golden MR. Racial/ethnic 
disparities in the lifetime risk of Chlamydia trachomatis diagnosis and adverse reproductive health 
outcomes among women in King County, Washington. Clin Infect Dis 2018; 67:593–9. [PubMed: 
29420716] 
5. Gaydos C, Hardick J. Point of care diagnostics for sexually transmitted infections: perspectives and 
advances. Expert Rev Anti Infect Ther 2014; 12:657–72. [PubMed: 24484215] 
6. Hui BB, Wilson DP, Ward JS, et al. The potential impact of new generation molecular point-of-care 
tests on gonorrhoea and chlamydia in a setting of high endemic prevalence. Sex Health 2013; 
10:348–56. [PubMed: 23806149] 
7. Vickerman P, Watts C, Peeling RW, Mabey D, Alary M. Modelling the cost effectiveness of rapid 
point of care diagnostic tests for the control of HIV and other sexually transmitted infections among 
female sex workers. Sex Transm Infect 2006; 82:403–12. [PubMed: 17012515] 
Rönn et al. Page 8
Clin Infect Dis. Author manuscript; available in PMC 2021 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
8. Cook RL, Hutchison SL, Østergaard L, Braithwaite RS, Ness RB. Systematic review: noninvasive 
testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005; 142:914–25. 
[PubMed: 15941699] 
9. The National Committee for Quality Assurance. The state of health care quality report. 2015 
Available at: store.ncqa.org/index.php/catalog/product/view/id/2341/s/2015-state-of-health-care-
quality-report/. Accessed 2 July 2019.
10. Davies B, Turner KME, Benfield T, et al.; Danish Chlamydia Study. Pelvic inflammatory disease 
risk following negative results from chlamydia nucleic acid amplification tests (NAATs) versus 
non-NAATs in Denmark: a retrospective cohort. PLOS Med 2018; 15:e1002483. [PubMed: 
29293503] 
11. Foglia G, Rhodes P, Goldberg M, St Louis ME. Completeness of and duration of time before 
treatment after screening women for Chlamydia trachomatis infections. Sex Transm Dis 1999; 
26:421–5. [PubMed: 10494931] 
12. Schwebke JR, Sadler R, Sutton JM, Hook EW 3rd. Positive screening tests for gonorrhea and 
chlamydial infection fail to lead consistently to treatment of patients attending a sexually 
transmitted disease clinic. Sex Transm Dis 1997; 24:181–4. [PubMed: 9101628] 
13. Hwang LY, Tebb KP, Shafer MA, Pantell RH. Examination of the treatment and follow-up care for 
adolescents who test positive for Chlamydia trachomatis infection. Arch Pediatr Adolesc Med 
2005; 159:1162–6. [PubMed: 16330741] 
14. Wong D, Berman SM, Furness BW, Gunn RA, Taylor M, Peterman TA. Time to treatment for 
women with chlamydial or gonococcal infections: a comparative evaluation of sexually transmitted 
disease clinics in 3 US cities. Sex Transm Dis 2005; 32:194–8. [PubMed: 15729159] 
15. Yoon J, Elder HR, Hawrusik R, Klevens RM, Roosevelt KA, Hsu KK. Does nonmetropolitan 
residence impact timely chlamydia treatment in Massachusetts? Sex Transm Dis 2018; 45:e52–6. 
[PubMed: 29498967] 
16. The National Committee for Quality Assurance. Chlamydia screening in women. Available at: 
https://www.ncqa.org/hedis/measures/chlamydia-screening-in-women/. Accessed 4 April 2019.
17. Rönn MM, Tuite AR, Menzies NA, et al. The impact of screening and partner notification on 
chlamydia prevalence and numbers of infections averted in the United States, 2000–2015: 
evaluation of epidemiologic trends using a pair-formation transmission model. Am J Epidemiol 
2019; 188:545–54. [PubMed: 30608525] 
18. Dagnan D, Chadwick P, Proudlove J. Toward an assessment of suitability of people with mental 
retardation for cognitive therapy. Cognit Ther Res 2000; 24:627–36.
19. Centers for Disease Control and Prevention. NCHHSTP AtlasPlus. Updated 2017. Available at: 
https://www.cdc.gov/nchhstp/atlas/index.htm. Accessed 16 November 2017.
20. Centers for Disease Control and Prevention. Youth risk behavior survey data & documentation. 
Available at: https://www.cdc.gov/healthyyouth/data/yrbs/data.htm. Accessed 2 July 2019.
21. Trikalinos T. Pelvic inflammatory disease development due to chlamydia. Available at: https://
www.brown.edu/public-health/cesh/resources/technical-reports. Accessed 2 July 2019.
22. Davies B, Ward H, Leung S, et al. Heterogeneity in risk of pelvic inflammatory diseases after 
chlamydia infection: a population-based study in Manitoba, Canada. J Infect Dis 2014; 210(Suppl 
2):S549–55. [PubMed: 25381374] 
23. Davies B, Turner KME, Frølund M, et al.; Danish Chlamydia Study Group. Risk of reproductive 
complications following chlamydia testing: a population-based retrospective cohort study in 
Denmark. Lancet Infect Dis 2016; 16:1057–64. [PubMed: 27289389] 
24. Widdice LE, Hsieh YH, Silver B, Barnes M, Barnes P, Gaydos CA. Performance of the atlas 
genetics rapid test for Chlamydia trachomatis and women’s attitudes toward point-of-care testing. 
Sex Transm Dis 2018; 45:723–7. [PubMed: 29771869] 
25. LeFevre ML; U.S. Preventive Services Task Force. Screening for chlamydia and gonorrhea: U.S. 
Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 161:902–10. 
[PubMed: 25243785] 
26. Barnett SD, Brundage JF. Incidence of recurrent diagnoses of Chlamydia trachomatis genital 
infections among male and female soldiers of the US Army. Sex Transm Infect 2001; 77:33–6. 
[PubMed: 11158689] 
Rönn et al. Page 9
Clin Infect Dis. Author manuscript; available in PMC 2021 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
27. Lewis FM, Newman DR, Anschuetz GL, Mettey A, Asbel L, Salmon ME. Partner meeting place is 
significantly associated with gonorrhea and chlamydia in adolescents participating in a large high 
school sexually transmitted disease screening program. Sex Transm Dis 2014; 41:605–10. 
[PubMed: 25211256] 
28. Learner ER, Torrone EA, Fine JP, Pence BW, Powers KA, Miller WC. Chlamydia prevalence 
trends among women and men entering the National Job Training Program from 1990 through 
2012. Sex Transm Dis 2018; 45:554–9. [PubMed: 29465650] 
29. Whitlock GG, Gibbons DC, Longford N, Harvey MJ, McOwan A, Adams EJ. Rapid testing and 
treatment for sexually transmitted infections improve patient care and yield public health benefits. 
Int J STD AIDS 2018; 29:474–82. [PubMed: 29059032] 
30. Birger R, Saunders J, Estcourt C, et al. Should we screen for the sexually-transmitted infection 
Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model. Sci Rep 2017; 
7:16162. [PubMed: 29170443] 
31. Fajardo-Bernal L, Aponte-Gonzalez J, Vigil P, et al. Home-based versus clinic-based specimen 
collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections. 
Cochrane Database Syst Rev 2015; 9:CD011317.
32. Niccolai LM, Winston DM. Physicians’ opinions on partner management for nonviral sexually 
transmitted infections. Am J Prev Med 2005; 28:229–33. [PubMed: 15710281] 
33. Qin JZ, Diniz CP, Coleman JS. Pharmacy-level barriers to implementing expedited partner therapy 
in Baltimore, Maryland. Am J Obstet Gynecol 2018; 218:504. e1–6. [PubMed: 29410060] 
34. Peterman TA, Kreisel K, Habel MA, Pearson WS, Dittus PJ, Papp JR. Preparing for the chlamydia 
and gonorrhea self-test. Sex Transm Dis 2018; 45:e7–9. [PubMed: 29420452] 
35. Rompalo AM, Hsieh YH, Hogan T, et al. Point-of-care tests for sexually transmissible infections: 
what do “end users” want? Sex Health 2013; 10:541–5. [PubMed: 24160838] 
36. Huang W, Gaydos CA, Barnes MR, Jett-Goheen M, Blake DR. Comparative effectiveness of a 
rapid point-of-care test for detection of Chlamydia trachomatis among women in a clinical setting. 
Sex Transm Infect 2013; 89:108–14. [PubMed: 22984085] 
37. Gaydos CA, Van Der Pol B, Jett-Goheen M, et al.; Chlamydia trachomatis and Neisseria 
gonorrhoeae Study Group. Performance of the cepheid CT/NG Xpert rapid PCR test for detection 
of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 2013; 51:1666–72. 
[PubMed: 23467600] 
38. Gaydos CA. Review of use of a new rapid real-time PCR, the Cepheid GeneXpert® (Xpert) 
CT/NG assay, for Chlamydia trachomatis and Neisseria gonorrhoeae: results for patients while in a 
clinical setting. Expert Rev Mol Diagn 2014; 14:135–7. [PubMed: 24450867] 
39. Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook EW 3rd. The natural history of 
untreated Chlamydia trachomatis infection in the interval between screening and returning for 
treatment. Sex Transm Dis 2008; 35:119–23. [PubMed: 17898680] 
Rönn et al. Page 10
Clin Infect Dis. Author manuscript; available in PMC 2021 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Impact of POCT in Analysis 1. Outcomes of the chlamydia burden among women aged 15–
24, presented under different assumptions about POCT sensitivity (varied between 90–99%), 
the proportion of patients treated immediately (30–100%), the baseline proportion of LTFU 
(5–20%), and the average baseline delay between testing positive and being treated (1–3 
weeks). (A) Prevalence reductions relative to baseline, (B) annual infections, and (C) annual 
PID cases averted are shown. Samples of 8000 simulations are plotted for each scenario. 
Abbreviations: LTFU, loss to follow-up; PID, pelvic inflammatory disease; POCT, point-of-
care testing; wk, week.
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Figure 2. 
Impact of POCT if screening frequency is increased by 20% in Analysis 2. Outcomes of the 
chlamydia burden among women aged 15–24 are presented under different assumptions 
about POCT sensitivity (varied 90–99%), the proportion of patients treated immediately 
(30–60%), the baseline proportion of LTFU (5–20%), and the average baseline delay 
between testing positive and being treated (1–3 weeks). (A) Prevalence reductions relative to 
baseline, (B) annual infections, and (C) annual PID cases averted are shown. Samples of 
8000 simulations are plotted for each scenario. Abbreviations. LTFU, loss to follow-up; PID, 
pelvic inflammatory disease; POCT, point-of-care testing; wk, week.
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